24/7 Market News Snapshot 20 October, 2025 – Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA)
DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (NASDAQ:VRCA) are discussed in this article.
Verrica Pharmaceuticals Inc. (VRCA) is witnessing notable market momentum, opening at $4.17 and currently trading at $4.69, representing a compelling increase of approximately 13.06%. This trading activity, with a volume of 1.62 million shares, reflects heightened investor enthusiasm and potential volatility surrounding the company’s recent announcements. Key technical indicators suggest that investors should watch resistance levels around $4.75 and support near $4.40. A sustained price movement beyond the resistance could signal further bullish trends, while any decline below the support level may indicate caution.
Additionally, the company has made significant strides in its regulatory endeavors concerning YCANTH® (VP-102), a novel treatment for molluscum contagiosum. Following constructive dialogues with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), Verrica is set to initiate the Marketing Authorization Application (MAA) process in the European Union. The CHMP has recognized that data from prior Phase 3 studies conducted in the United States and Japan is sufficient to support this filing, thereby validating the product’s efficacy and safety profile without requiring further studies.
Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica, expressed optimism regarding the alignment with CHMP, highlighting the clinical viability of YCANTH and the potential to address the unmet needs of millions affected by this common pediatric skin condition. YCANTH is distinguished as the first healthcare professional-administered therapy approved by the FDA for molluscum contagiosum, utilizing a targeted single-use applicator to optimize treatment efficacy.
With an estimated coverage of approximately 225 million lives for YCANTH treatment, Verrica remains committed to enhancing patient care options and is exploring strategic opportunities to maximize the product’s impact in the European market, reinforcing its dedication to innovation in dermatological therapies.
Related news for (VRCA)
- Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
- Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
- 24/7 Market News Snapshot 07 October, 2025 – Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA)